Health Care·Biotechnology·$161.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.00 | N/A | +11.48% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.00 | N/A | +11.48% |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management remains focused on innovation and pipeline development. They did not provide specific guidance for the upcoming quarters.
Management highlighted ongoing research and development efforts.
They emphasized the importance of maintaining a strong pipeline.
No specific guidance was provided for future quarters.
Gilead Sciences reported better-than-expected earnings per share, indicating strong performance in certain areas. However, the lack of revenue data and guidance leaves some uncertainty about future performance. The stock reaction is not available, which makes it difficult to gauge investor sentiment following the report.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CANADIAN NATL RY CO
Oct 22, 2012